IRIS
VOSO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 71.117
AS - Asia 6.760
EU - Europa 4.913
SA - Sud America 1.395
AF - Africa 119
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 26
Totale 84.358
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 70.951
SG - Singapore 3.364
IT - Italia 1.195
BR - Brasile 1.189
CN - Cina 1.150
HK - Hong Kong 942
IE - Irlanda 766
UA - Ucraina 679
DE - Germania 599
KR - Corea 491
RU - Federazione Russa 438
VN - Vietnam 327
GB - Regno Unito 326
FI - Finlandia 227
FR - Francia 181
NL - Olanda 106
IN - India 100
SE - Svezia 95
CA - Canada 92
PL - Polonia 90
AR - Argentina 75
AT - Austria 70
ID - Indonesia 64
BD - Bangladesh 58
JP - Giappone 55
MX - Messico 50
ES - Italia 44
ZA - Sudafrica 42
EC - Ecuador 28
AU - Australia 27
CO - Colombia 27
IQ - Iraq 25
TR - Turchia 22
PK - Pakistan 21
PY - Paraguay 21
MA - Marocco 20
VE - Venezuela 20
EU - Europa 19
UZ - Uzbekistan 19
BE - Belgio 18
IR - Iran 18
EG - Egitto 17
LT - Lituania 15
KZ - Kazakistan 14
JO - Giordania 11
KE - Kenya 11
PE - Perù 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 9
CH - Svizzera 9
CL - Cile 9
CZ - Repubblica Ceca 9
PH - Filippine 9
DZ - Algeria 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
AL - Albania 6
TN - Tunisia 6
DO - Repubblica Dominicana 5
IL - Israele 5
KG - Kirghizistan 5
RO - Romania 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BG - Bulgaria 4
BN - Brunei Darussalam 4
CR - Costa Rica 4
HU - Ungheria 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
GR - Grecia 3
GT - Guatemala 3
HR - Croazia 3
LU - Lussemburgo 3
MK - Macedonia 3
MY - Malesia 3
NP - Nepal 3
PS - Palestinian Territory 3
RS - Serbia 3
TH - Thailandia 3
A1 - Anonimo 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BY - Bielorussia 2
GE - Georgia 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MD - Moldavia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
QA - Qatar 2
SD - Sudan 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AO - Angola 1
BB - Barbados 1
Totale 84.340
Salva come PNG Salva come JPEG
Città #
Houston 22.121
Woodbridge 18.291
Wilmington 16.089
Fairfield 2.305
Singapore 1.694
Ann Arbor 1.484
Ashburn 1.243
Hong Kong 934
Seattle 906
Cambridge 834
Chandler 819
Dublin 705
Jacksonville 591
Dearborn 574
Beijing 538
Medford 526
Rome 400
Santa Clara 320
Dallas 311
New York 283
Lawrence 252
The Dalles 238
Los Angeles 199
Hangzhou 131
Ho Chi Minh City 123
Buffalo 118
San Diego 117
Milan 107
Moscow 107
São Paulo 103
Menlo Park 102
Council Bluffs 87
London 86
Nuremberg 66
Redondo Beach 59
Hanoi 58
Boardman 55
Chicago 55
Creede 52
Center 51
Munich 51
Norwalk 41
Seoul 41
Engelhard 40
Jakarta 40
Warsaw 40
Kraków 39
Shanghai 34
Tokyo 34
Toronto 34
Brooklyn 33
Denver 33
Zhengzhou 33
Rio de Janeiro 32
Nanjing 31
Vienna 31
Guangzhou 30
Hefei 30
Helsinki 29
Montreal 28
Mountain View 28
Orem 28
Hackensack 26
Stockholm 26
Verona 25
Belo Horizonte 24
Bologna 24
Redwood City 24
Florence 23
Lappeenranta 23
Phoenix 23
San Francisco 23
Brasília 22
Atlanta 21
Amsterdam 20
Chennai 20
Johannesburg 20
Naples 20
Curitiba 19
Detroit 18
Guarulhos 18
Kunming 18
Pune 18
Frankfurt am Main 17
Haiphong 16
Porto Alegre 16
Baghdad 15
Boston 15
Brussels 15
Dhaka 15
Monte Vista 15
Poplar 15
Da Nang 14
Mexico City 14
Cape Town 13
Columbus 13
Goiânia 13
Nanchang 13
Salvador 13
Turku 13
Totale 74.594
Salva come PNG Salva come JPEG
Nome #
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation 2.362
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias 1.655
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS 1.612
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15 1.249
Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis 1.175
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 496
Therapy-related leukemia and myelodysplasia: susceptibility and incidence 493
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 483
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 460
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 452
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 447
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 446
Clonal evolution in therapy-related neoplasms 443
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia 441
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 441
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 440
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 440
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy 439
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 438
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 436
Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor 435
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 428
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin 428
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression 426
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 425
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 424
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer 424
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 423
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 422
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 422
Panobinostat for the treatment of acute myelogenous leukemia 422
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia 422
New treatments for myelodysplastic syndromes 421
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 420
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery 418
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 417
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 414
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms 414
Therapy related leukemias: susceptibility, prevention and treatment 413
Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease 412
Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms 411
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 411
Small lymphocytic lymphoma in a patient with Fabry disease 409
Prevalence of obesity in young adults with acute lymphoblastic leukemia 409
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 408
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 408
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 407
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 406
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 405
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System 405
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation 404
Mobilization and selection of CD34+ cells 403
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 402
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 402
Hepato-splenic mycotic abscesses in patients with acute leukemia 401
In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study 400
Why methylation is not a marker predictive of response to hypomethylating agents 399
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? 398
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects 398
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 398
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes 397
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 396
Epigenetic changes in therapy-related MDS/AML 395
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 393
High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment 393
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia 393
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients 392
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 392
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 391
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 391
Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer 390
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma 389
Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre 388
Incidence and susceptibility to therapy-related myeloid neoplasms 387
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 387
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression 386
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 386
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 386
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia 385
Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia 385
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha 385
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content 384
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 384
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 384
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 384
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias 383
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma 383
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 381
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 380
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 379
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 378
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B 378
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 378
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 376
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 375
Treatment of low-blast count AML using hypomethylating agents 374
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 373
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 372
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 372
Inhibition of hematopoiesis by competitive binding of transcription factor PU.1 372
Totale 46.739
Salva come PNG Salva come JPEG
Categoria #
all - tutte 204.571
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 204.571
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.647 0 0 0 0 0 1.094 1.365 1.083 285 266 447 107
2021/20222.487 118 293 127 61 78 198 129 148 178 143 268 746
2022/20232.760 339 173 135 270 180 696 484 119 205 20 77 62
2023/20241.297 126 37 149 56 124 346 67 33 51 40 30 238
2024/20256.762 179 1.438 783 446 133 355 681 337 799 568 568 475
2025/20265.178 916 611 1.522 879 966 284 0 0 0 0 0 0
Totale 85.725